Literature DB >> 23318696

Pharmacological treatment of neonatal seizures: a systematic review.

Laurel A Slaughter1, Anup D Patel, Jonathan L Slaughter.   

Abstract

Pharmacologic treatment options for neonatal seizures have expanded over the past 2 decades, and there is no consensus on optimal treatment strategy. We systematically reviewed the published literature to determine which medication(s) are most effective for treating neonatal seizures, by retrieving trials and observational investigations via PubMed (through August 2011) that focused on pharmacological seizure treatment of neonates (≤ 28 days old) and utilized continuous or amplitude-integrated EEG to confirm seizure diagnosis and cessation. Our search identified 557 initial articles and 14 additional studies after reference reviews, with 16 meeting inclusion criteria. Of these, 2 were randomized trials and only 3 additional investigations included comparison groups. We found limited evidence regarding the best pharmacologic treatment for neonatal seizures, but were able to devise a treatment algorithm from available data. These findings have the potential to serve as a clinical reference and to inform the design of comparative effectiveness investigations for neonatal antiepileptics.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23318696      PMCID: PMC3805825          DOI: 10.1177/0883073812470734

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  50 in total

1.  Electroencephalograms, clinical observations and the monitoring of neonatal seizures.

Authors:  A Bye; D Flanagan
Journal:  J Paediatr Child Health       Date:  1995-12       Impact factor: 1.954

2.  Midazolam in the treatment of refractory neonatal seizures.

Authors:  R D Sheth; D J Buckley; A R Gutierrez; M Gingold; J B Bodensteiner; S Penney
Journal:  Clin Neuropharmacol       Date:  1996-04       Impact factor: 1.592

3.  Sinoatrial arrest: an interaction between phenytoin and lignocaine.

Authors:  R A Wood
Journal:  Br Med J       Date:  1971-03-20

4.  Systolic blood pressure and blood volume in preterm infants.

Authors:  K Bauer; O Linderkamp; H T Versmold
Journal:  Arch Dis Child       Date:  1993-11       Impact factor: 3.791

5.  Thiopental efficacy in phenobarbital-resistant neonatal seizures.

Authors:  M Bonati; G Marraro; A Celardo; F Passerini; F Schieroni; P Spada; R Valsecchi; E De Capitani
Journal:  Dev Pharmacol Ther       Date:  1990

6.  Clinical and EEG response to anticonvulsants in neonatal seizures.

Authors:  J Connell; R Oozeer; L de Vries; L M Dubowitz; V Dubowitz
Journal:  Arch Dis Child       Date:  1989-04       Impact factor: 3.791

7.  Lorazepam in the treatment of refractory neonatal seizures.

Authors:  J Maytal; G P Novak; K C King
Journal:  J Child Neurol       Date:  1991-10       Impact factor: 1.987

8.  A population-based study of neonatal seizures in Fayette County, Kentucky.

Authors:  M J Lanska; D J Lanska; R J Baumann; R J Kryscio
Journal:  Neurology       Date:  1995-04       Impact factor: 9.910

9.  Lorazepam in the treatment of refractory neonatal seizures. A pilot study.

Authors:  A Deshmukh; W Wittert; E Schnitzler; H H Mangurten
Journal:  Am J Dis Child       Date:  1986-10

10.  Neonatal phenobarbital and phenytoin binding profiles.

Authors:  M J Painter; M B Minnigh; L Gaus; M Scher; B Brozanski; J Alvin
Journal:  J Clin Pharmacol       Date:  1994-04       Impact factor: 3.126

View more
  27 in total

Review 1.  Pharmacotherapy for Seizures in Neonates with Hypoxic Ischemic Encephalopathy.

Authors:  Elissa Yozawitz; Arthur Stacey; Ronit M Pressler
Journal:  Paediatr Drugs       Date:  2017-12       Impact factor: 3.022

Review 2.  Treating disorders of the neonatal central nervous system: pharmacokinetic and pharmacodynamic considerations with a focus on antiepileptics.

Authors:  Maria D Donovan; Geraldine B Boylan; Deirdre M Murray; John F Cryan; Brendan T Griffin
Journal:  Br J Clin Pharmacol       Date:  2015-11-04       Impact factor: 4.335

3.  EEG Monitoring Technique Influences the Management of Hypoxic-Ischemic Seizures in Neonates Undergoing Therapeutic Hypothermia.

Authors:  Saber Jan; Frances J Northington; Charlamaine M Parkinson; Carl E Stafstrom
Journal:  Dev Neurosci       Date:  2017-01-17       Impact factor: 2.984

4.  Impact of Drug Treatment at Neonatal Ages on Variability of Drug Metabolism and Drug-drug Interactions in Adult Life.

Authors:  Stephanie Piekos; Chad Pope; Austin Ferrara; Xiao-Bo Zhong
Journal:  Curr Pharmacol Rep       Date:  2017-01-03

5.  Targeting ischemia-induced KCC2 hypofunction rescues refractory neonatal seizures and mitigates epileptogenesis in a mouse model.

Authors:  Brennan J Sullivan; Pavel A Kipnis; Brandon M Carter; Li-Rong Shao; Shilpa D Kadam
Journal:  Sci Signal       Date:  2021-11-09       Impact factor: 8.192

Review 6.  Neonatal seizures: advances in mechanisms and management.

Authors:  Hannah C Glass
Journal:  Clin Perinatol       Date:  2013-12-12       Impact factor: 3.430

Review 7.  Pharmacotherapy for Neonatal Seizures: Current Knowledge and Future Perspectives.

Authors:  Maria D Donovan; Brendan T Griffin; Liudmila Kharoshankaya; John F Cryan; Geraldine B Boylan
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

8.  The effects of adding prophylactic phenobarbital to therapeutic hypothermia in the term-equivalent hypoxic-ischemic rat.

Authors:  Sushma Krishna; Alexandra Hutton; Eric Aronowitz; Holly Moore; Susan J Vannucci
Journal:  Pediatr Res       Date:  2017-11-22       Impact factor: 3.756

9.  Caffeine Protects Against Anticonvulsant-Induced Impaired Neurogenesis in the Developing Rat Brain.

Authors:  Stefanie Endesfelder; Ulrike Weichelt; Cornelia Schiller; Katja Winter; Clarissa von Haefen; Christoph Bührer
Journal:  Neurotox Res       Date:  2018-02-07       Impact factor: 3.911

10.  Neonatal seizures therapy: we are still looking for the efficacious drug.

Authors:  Carlotta Spagnoli; Elena Pavlidis; Francesco Pisani
Journal:  Ital J Pediatr       Date:  2013-06-05       Impact factor: 2.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.